New Drug: Amivantamab for NSCLC
Study
Phase 3, international, randomized trial (PAPILLON)
|
Advanced NSCLC with EGFR exon 20 insertions who had not received previous systemic therapy
|
Amivantamab + Chemoterapy (n=153) vs. Chemotherapy (n=155)
|
|
Efficacy
mPFS: 11.4 vs. 6.7 mos, HR:0.40, p<0.001
|
18 mos PFS: 31% vs. 3%
|
ORR: 73% vs. 47%
|
mDoR: 9.7 vs. 4.4 mos
|
Safety
• Grade3: Neutropenia (33% vs. 23%), anemia (11% vs. 12%), thrombocytopenia (10% vs. 10%), rash (11% vs. 0)
|
Zhou C Amivantamab plus Chemotherapy in NSCLC with EGFR Exon 20 Insertions
Reviewed by Ulas D. Bayraktar, MD on Jan 13, 2024
